In recent years, a critical need in the Parkinson's Disease (PD) research community has been access to well-characterized antibodies that can be used to efficiently detect and purify Leucine-Rich Repeat Kinase 2 (LRRK2) protein. The Michael J. Fox Foundation (MJFF) has supported this effort by partnering with Dr. Dario Alessi (MRC Protein Phosphorylation Unit, University of Dundee) to help accelerate LRRK2 research. Dr. Alessi has characterized unique and high quality LRRK2 rabbit monoclonal antibodies, generated by Epitomics, to be made widely available for PD research community.

LRRK2 (Leucine-rich repeat kinase 2, dardarin) is a multi-domain protein belonging to the ROCO family of proteins that contains a kinase and GTPase domain among its many protein interaction domains. LRRK2 is mutated in a significant number of Parkinson's disease (PD) patients. Mutations in this gene account for 4% of PD, and are observed in 1% of sporadic PD patients. The most common mutation replaces glycine 2019 with a serine that results in increased LRRK2 kinase activity. This indicates that inhibitors of LRRK2 kinase activity might be of therapeutic benefit for the treatment of Parkinson’s disease and has stimulated much activity in this field of research.

The Dundee-MJFF LRRK2[100-500] total antibody will be of great utility in further understanding LRRK2 as it relates to Parkinson’s disease. It should be noted this antibody is highly selective and sensitive and can readily be used to monitor LRRK2 protein levels in immunoblot analysis of 2-20 microgram amounts of whole cell extract. The LRRK2[100-500] total antibody recognizes both mouse and human endogenous LRRK2.

This product is a recombinant monoclonal antibody, which offers several advantages including:

• - High batch-to-batch consistency and reproducibility
• - Improved sensitivity and specificity
• - Long-term security of supply
• - Animal-free production

Our RabMAb^® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb^® patents.

We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.